RT Journal Article SR Electronic T1 Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.03.20187252 DO 10.1101/2020.09.03.20187252 A1 Agarwal, Anup A1 Mukherjee, Aparna A1 Kumar, Gunjan A1 Chatterjee, Pranab A1 Bhatnagar, Tarun A1 Malhotra, Pankaj A1 Latha, B A1 Bundas, Sunita A1 Kumar, Vivek A1 Dosi, Ravi A1 Khambholja, Janak Kumar A1 de Souza, Rosemarie A1 Mesipogu, Raja Rao A1 Srivastava, Saurabh A1 Dube, Simmi A1 Chaudhary, Kiran A1 S, Subash A1 Mattuvar K, S. Anbuselvi A1 Rajendran, V A1 Sundararajaperumal, A A1 Balamanikandan, P A1 Maheswari, R S Uma A1 Jayanthi, R A1 Ragunanthanan, S A1 Bhandari, Sudhir A1 Singh, Ajeet A1 Pal, Ashok A1 Handa, Anjali A1 Rankawat, Govind A1 Kargirwar, Ketan A1 Regi, Joyce A1 Rathod, Darshana A1 Pathrose, Edwin A1 Bhutaka, Nirankar A1 Patel, Mayur H A1 Verma, Rahul J A1 Malukani, Kamal A1 Patel, Shivani A1 Thakur, Apurv A1 Joshi, Satish A1 Kulkarni, Rashmi A1 Suthar, Nilay N A1 Shah, Nehal M A1 Purohit, Hemang M A1 Shah, Cherry K A1 Patel, Monila N A1 Shah, Saket A1 Shah, Smit H A1 Memon, Tehsim A1 Beriwala, Vishal R A1 Jashnani, Kusum A1 Ezzy, Fatema A1 Agrawal, Simran A1 Bhadade, Rakesh A1 N, Atish M A1 Madke, Tushar A1 Kavishwar, Vikash A1 Waghmare, Ramesh A1 Valvi, Nitin A1 Chander, B Thrilok A1 Sekhar, A Vinaya A1 Maurya, Akhilesh Kumar A1 Hemanth, K A1 Nagamani, K A1 Sudha, K A1 Chandra, T Ravi A1 Rao, K Tushara A1 Vyshnavi, J A1 Upadhyay, Rashmi A1 Bahadur, Shalini A1 Pathak, Rambha A1 Seth, Shikha A1 Gupta, Rakesh A1 Saxena, Rita A1 Dwivedi, Preksha A1 Malik, Reeni A1 Chourasia, Deepti A1 Lalwani, Jaya A1 Sharma, UM A1 Marko, JL A1 Suri, Amit A1 Kumar, Vijay A1 Kaushik, Rajnish A1 Kodan, Parul A1 Acharya, Bhabani Prasad A1 Gaur, Kuldeep Kumar A1 Gupta, Anubhav A1 Sachdeva, Prerna A1 Dogra, Shruti A1 Jindal, Aikaj A1 John, M Joseph A1 Dhanju, Avtar Singh A1 Khetrepal, Ranjana A1 Sharma, Neeraj A1 Kukar, Neetu A1 Kavita, Divya A1 Kumar, Rajesh A1 Mahajan, Rajesh A1 Singh, Gurpreet A1 Kaur, Jaspreet A1 Singh, Raminder Pal A1 Bassi, Rajni A1 Parikh, Swapneil A1 Shrivastav, Om A1 Shastri, Jayanthi A1 Desai, Maherra A1 Udupa, Shreevatsa A1 Bafna, Varun A A1 Barge, Vijay A1 Madane, Rajendra A1 Yadav, Sheetal A1 Mishra, Sanjeev A1 Bajpayee, Archana A1 Garg, M K A1 Bohra, G K A1 Nag, Vijaylakshmi A1 Anne, Puneeth Babu A1 Nadeem, Mohd A1 Singh, Pallavi A1 Niwas, Ram A1 Khaire, Niranjan Shiwaji A1 Sharma, Rattiram A1 Singh, Mini p A1 Sachdeva, Naresh A1 Sachdev, Suchet A1 Hans, Rekha A1 Suri, Vikas A1 Yaddanapudi, L N A1 Lakshmi, PVM A1 Singh, Neha A1 Bhushan, Divendu A1 Kumar, Neeraj A1 Tambe, Muralidhar A1 Salvi, Sonali A1 Kadgi, Nalini A1 Sangle, Shashikala A1 Nakate, Leena A1 Joshi, Samir A1 Karyakarte, Rajesh A1 Goyanka, Suraj A1 Sharma, Nimisha A1 Verma, Nikhil A1 Das, Asim A1 Bahl, Monika A1 Wadhwa, Nitya A1 Bhat, Shreepad A1 Deshmukh, Shweta A1 Wagh, Vrushali A1 Kulkarni, Atul A1 Yardi, Tanvi A1 Kalgud, Ram S A1 Reddy, Purushottam A1 Yevoor, Kavitha A1 Gajula, Prashanth A1 Maleyur, Vivek A1 S, Medini A1 HN, Mohith A1 Gurtoo, Anil A1 Sud, Ritika A1 Pahuja, Sangeeta A1 Prakash, Anupam A1 Gogoi, Parijat A1 Shukla, Shailja A1 Reddy, D Himanshu A1 Chandra, Tulika A1 Pandey, Saurabh A1 Maurya, Pradeep A1 Wahid, Ali A1 Kumar, Vivek A1 Upadhyay, Kamlesh A1 Bhatnagar, Nidhi A1 Shah, Nilima A1 Shah, Mamta A1 Patel, Tarak A1 Jaiswal, Ram Mohan A1 Jain, Ashish A1 Sharma, Shweta A1 Rijhwani, Puneet A1 Gupta, Naveen A1 Patel, Tinkal C A1 Solu, Mahesh G A1 Patel, Jitendra A1 Shah, Yash R A1 Jarag, Mayur A1 Godbole, Varsha A1 Shah, Meenakshi A1 Raj, Rikin A1 Nagori, Irfan A1 Jha, Pramod R A1 Shah, Arti D A1 Yeeli, Gowtham A1 Jain, Archit A1 Gill, Rooppreet Kaur A1 Babu, KV Sreedhar A1 Babu, B Suresh A1 Mohan, Alladi A1 Vengamma, B A1 Sekhar, K Chandra A1 Damam, Srinivasulu A1 Narsimhulu, K A1 Aparna, C A1 Baleswari, G A1 K, Ravindranath Reddy A1 Chandrasekhar, P A1 Panjwani, Sunil Jodharam A1 Akholkar, Pankaj J A1 Joshi, Kairavi Parthesh A1 Shah, Pragnesh H A1 Barvaliya, Manish A1 Baldi, Milind A1 Yadav, Ashok A1 Gupta, Manoj A1 Rawat, Nitin A1 Chawda, Dilip A1 Natarajan, M A1 Sintha, M A1 Kumar, David Pradeep A1 Rabbani, Fathhur A1 Khadke, Vrushali Khirid A1 Patki, Dattatray A1 Marathe, Sonali A1 D Souza, Clyde A1 Tadha, Vipul A1 Arora, Satyam A1 Gupta, Devendra Kumar A1 Dua, Seema A1 Chauhan, Nitu A1 Chahar, Ajeet Singh A1 Mammen, Joy John A1 Kumar, Snehil A1 Daniel, Dolly A1 Singh, Ravindraa A1 Dhat, Venkatesh A1 Agarwal, Yogesh A1 Arora, Sohini A1 Pathak, Ashish A1 Purohit, Manju A1 Sharma, Ashish A1 Sharma, Jayashree A1 Madkaikar, Manisha A1 Joshi, Kavita A1 Yadav, Reetika Malik A1 Bhagwat, Swarupa A1 Karnik, Niteen D A1 Gokhale, Yojana A A1 Naik, Leena A1 Margam, Sangita A1 Das, Santasabuj A1 Turuk, Alka A1 Kumar, V Saravana A1 Kanagasabai, K A1 Sabarinathan, R A1 Deshpande, Gururaj A1 Sharma, Sharda A1 Gunjikar, Rashmi A1 Shete, Anita A1 Phagiwala, Darpan A1 Patil, Chetan A1 Shingade, Snehal A1 Jarande, Kajal A1 Kaushal, Himanshu A1 Yadav, Pragya A1 Sapkal, Gajanan A1 Abraham, Priya YR 2020 UL http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187252.abstract AB Objectives: Convalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19. Design: Open-label, parallel-arm, phase II, multicentre, randomized controlled trial. Setting: Thirty-nine public and private hospitals across India. Participants: Hospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 ≤ 93% on room air). Intervention: Participants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm. Main Outcome Measure: Composite of progression to severe disease (PaO2/FiO2<100) or all-cause mortality at 28 days post-enrolment. Results: Between 22 nd April to 14 th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (14.5%) and 31 (13.5%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: 0.61 to 1.83]. Interpretation: CP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that TB is a member of the National Task Force for COVID-19 which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, RMY are employed with ICMR, the funding source for the trial. PC was an employee of ICMR during the trial. The funding source (ICMR) has no financial interest in the investigational product. No other author has any competing financial or non-financial interest.Clinical TrialCTRI/2020/04/024775Funding StatementThis multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved this study. The Central Implementation Team at ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in ICMR had no role in it. The funding source has no financial interest in the investigational product. The corresponding author at ICMR had access to all the data, is the guarantor for the current work and holds final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics comittee at the Indian council Medical Research, India and Intitutional review boards of all participating institutes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual patient level data, collected in connection with the PLACID Trial, along with a data dictionary defining the variable fields has been developed and is available with the corresponding author. De-identified participant level data with data dictionary, or a sub-set thereof, may be made available upon written request to the corresponding author. Additional documents, including the study protocol, statistical analysis plan have been made available as supplementary files within the original submission. Results of secondary or sub-group analyses will be provided on request. Data will be made available, upon request once the trial is published. Data requests should be accompanied by a brief proposal outlining the analysis plan, which may be carried out with investigator support. A signed data access agreement may be needed to ensure data safety and compliance with national rules regarding data sharing.